valganciclovir (Valcyte)
Jump to navigation
Jump to search
Indications
Dosage
- 900 mg PO BID for 21 days (active CMV retinitis)
- 900 mg QD maintenance
- see ref[4] for calculation of pediatric dosage
- maxmimum dose 900 mg BID[3][4]
Adverse effects
- potential carcinogen & teratogen
- do NOT handle broken tablets
Laboratory
Mechanism of action
Notes
Manufacturer: Roche
More general terms
Additional terms
References
- ↑ Prescriber's Letter 8(5):28 2001
- ↑ Department of Veterans Affairs, VA National Formulary
restricted to CMV retinitis - ↑ 3.0 3.1 FDA MedWatch Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225888.htm
- ↑ 4.0 4.1 4.2 FDA Drug Safety Announceement FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients http://www.fda.gov/Drugs/DrugSafety/ucm225727.htm
- ↑ 5.0 5.1 Deprecated Reference